BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Brainstorm Reports on Successful End of Phase 2 Meeting with FDA, Upcoming Phase 3 Trial and Planned Application for Hospital Exemption for NurOwn®
Conference Call @ 8:30am Eastern Time Today to Provide Corporate Update and Discuss Plans for 2017 HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 19, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative
View HTML
Toggle Summary 21st Century Cures Act Passed by U.S. Congress Provides an Accelerated Approval Pathway for Regenerative Medicine Therapies
Legislation Potentially Has Direct and Positive Implications for NurOwn® HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 15, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced its
View HTML
Toggle Summary In-Depth Analyses Presented at International Symposium on ALS/MND Suggest Strong Biological Effect for NurOwn®; Evidence of Halting of Disease Progression
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that new data from the Company's Phase 2 study of NurOwn ® in ALS were presented by lead
View HTML
Toggle Summary BrainStorm to Host Year End Call with Investors to Discuss Important Corporate Developments
Company Explores Regulatory Commercial Pathways for NurOwn® Conference Call and Live Webcast on December 19 at 8:30 am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 6, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell
View HTML
Toggle Summary BrainStorm Announces NurOwn® Data to be Highlighted at the 27th International Symposium on ALS/MND
Clinical Data to be Presented by James D. Berry, MD, MPH, and Anthony J. Windebank, MD, Principal Investigators in NurOwn® Phase 2 Trial HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 5, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 15, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter
View HTML
Toggle Summary BrainStorm Granted United States Patent for its Stem Cell Technology
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 31, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has been granted United States Patent No.
View HTML
Toggle Summary BrainStorm CEO to Present at Two Investor Conferences in September
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 6, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm CEO to Present at Two Investor Conferences in September
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 6, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 11, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter
View HTML
Toggle Summary BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS)
NurOwn® was Demonstrated to be Safe and Well Tolerated Clinically Meaningful Benefit Demonstrated by Higher Response to NurOwn® Compared to Placebo at All Time Points Conference Call and Live Webcast at 10am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ --
View HTML
Toggle Summary BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18
Conference Call and Live Webcast at 10am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , July 14, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the
View HTML
Toggle Summary BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 17, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits , Chief Executive Officer, will be presenting Thursday,
View HTML
Toggle Summary BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief Scientist
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 12, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 10, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter
View HTML
Toggle Summary Brainstorm to Present at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 29, 2016 /PRNewswire/ --  Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Dr. Yael Gothelf , VP Scientific & Regulatory Affairs will be
View HTML
Toggle Summary BrainStorm Announces Financial Results for 2015 and Provides Business Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 10, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2015
View HTML
Toggle Summary BrainStorm to Present at Bio-Asia-International and ARM Investor Day Conferences
NEW YORK and PETACH TIKVAH, Israel , March 8, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits , Chief Executive Officer, will be presenting at two upcoming
View HTML
Toggle Summary BrainStorm's NurOwn® for the Treatment of ALS Published in JAMA Neurology
Clinical Data Suggest that NurOwn Can Slow Disease Progression in ALS First Human Experience With Stem Cells Induced Under Culture to Produce Neurotrophic Factors (NTFs) Conference Call Today at 10:45am ET / 7:45am PT HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn® Trial in ALS at Hadassah Medical Center
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan. 11, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with Hadassah Medical
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds